{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:02:58Z","timestamp":1789599778747,"version":"build-2803163510"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40257-026-01046-x","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:05:58Z","timestamp":1780052758000},"page":"745-764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Understanding the Clinical Spectrum of the Cutaneous and Acute Hepatic Porphyrias"],"prefix":"10.1007","volume":"27","author":[{"given":"Toan N.","family":"Vu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahithi","family":"Talasila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Jeha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umer","family":"Nadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem F.","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry W.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-1649","authenticated-orcid":false,"given":"Stanislav N.","family":"Tolkachjov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"9","key":"1046_CR1","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1056\/NEJMra1608634","volume":"377","author":"DM Bissell","year":"2017","unstructured":"Bissell DM, Anderson KE, Bonkovsky HL. Porphyria. N Engl J Med. 2017;377(9):862\u201372. https:\/\/doi.org\/10.1056\/NEJMra1608634.","journal-title":"N Engl J Med"},{"issue":"3","key":"1046_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ymgme.2019.04.008","volume":"128","author":"JD Phillips","year":"2019","unstructured":"Phillips JD. Heme biosynthesis and the porphyrias. Mol Genet Metab. 2019;128(3):164\u201377. https:\/\/doi.org\/10.1016\/j.ymgme.2019.04.008.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"1046_CR3","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/jimd.12545","volume":"45","author":"S Lefever","year":"2022","unstructured":"Lefever S, Peersman N, Meersseman W, Cassiman D, Vermeersch P. Development and validation of diagnostic algorithms for the laboratory diagnosis of porphyrias. J Inherit Metab Dis. 2022;45(6):1151\u201362. https:\/\/doi.org\/10.1002\/jimd.12545.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"1046_CR4","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.gastro.2022.11.034","volume":"164","author":"B Wang","year":"2023","unstructured":"Wang B, Bonkovsky HL, Lim JK, Balwani M. AGA clinical practice update on diagnosis and management of acute hepatic porphyrias: expert review. Gastroenterology. 2023;164(3):484\u201391. https:\/\/doi.org\/10.1053\/j.gastro.2022.11.034.","journal-title":"Gastroenterology"},{"issue":"9718","key":"1046_CR5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","volume":"375","author":"H Puy","year":"2010","unstructured":"Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010;375(9718):924\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(09)61925-5.","journal-title":"Lancet"},{"issue":"3","key":"1046_CR6","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/phpp.12641","volume":"37","author":"I Snast","year":"2021","unstructured":"Snast I, Kaftory R, Lapidoth M, et al. Clinical features of genetic cutaneous porphyrias in Israel: a nationwide survey. Photodermatol Photoimmunol Photomed. 2021;37(3):236\u201342. https:\/\/doi.org\/10.1111\/phpp.12641.","journal-title":"Photodermatol Photoimmunol Photomed"},{"issue":"3","key":"1046_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.det.2014.03.001","volume":"32","author":"D Schulenburg-Brand","year":"2014","unstructured":"Schulenburg-Brand D, Katugampola R, Anstey AV, Badminton MN. The cutaneous porphyrias. Dermatol Clin. 2014;32(3):369\u201384. https:\/\/doi.org\/10.1016\/j.det.2014.03.001.","journal-title":"Dermatol Clin"},{"issue":"12","key":"1046_CR8","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1182\/blood-2007-04-088120","volume":"110","author":"SA Holme","year":"2007","unstructured":"Holme SA, Worwood M, Anstey AV, Elder GH, Badminton MN. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood. 2007;110(12):4108\u201310. https:\/\/doi.org\/10.1182\/blood-2007-04-088120.","journal-title":"Blood"},{"issue":"1","key":"1046_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/jmd2.12052","volume":"50","author":"H Naik","year":"2019","unstructured":"Naik H, Overbey JR, Desnick RJ, et al. Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X\u2010linked protoporphyria. JIMD Rep. 2019;50(1):9\u201319. https:\/\/doi.org\/10.1002\/jmd2.12052.","journal-title":"JIMD Rep"},{"key":"1046_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jdin.2025.05.017","volume":"22","author":"B Tran","year":"2025","unstructured":"Tran B, Raef H, Rebeiz L, et al. Impact of delay in diagnosis in patients with erythropoietic protoporphyria: a cross-sectional survey study. JAAD Int. 2025;22:60\u20133. https:\/\/doi.org\/10.1016\/j.jdin.2025.05.017.","journal-title":"JAAD Int"},{"key":"1046_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-med-042921-123602","volume":"75","author":"AK Dickey","year":"2024","unstructured":"Dickey AK, Leaf RK, Balwani M. Update on the porphyrias. Annu Rev Med. 2024;75:321\u201335. https:\/\/doi.org\/10.1146\/annurev-med-042921-123602.","journal-title":"Annu Rev Med"},{"issue":"12","key":"1046_CR12","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1373\/clinchem.2015.245456","volume":"61","author":"EW Gou","year":"2015","unstructured":"Gou EW, Balwani M, Bissell DM, et al. Pitfalls in erythrocyte protoporphyrin measurement for diagnosis and monitoring of protoporphyrias. Clin Chem. 2015;61(12):1453\u20136. https:\/\/doi.org\/10.1373\/clinchem.2015.245456.","journal-title":"Clin Chem"},{"issue":"2","key":"1046_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0738-081X(85)90034-3","volume":"3","author":"MB Poh-Fitzpatrick","year":"1985","unstructured":"Poh-Fitzpatrick MB. Porphyrin-sensitized cutaneous photosensitivity: pathogenesis and treatment. Clin Dermatol. 1985;3(2):41\u201382. https:\/\/doi.org\/10.1016\/0738-081X(85)90034-3.","journal-title":"Clin Dermatol"},{"issue":"3","key":"1046_CR14","first-page":"148","volume":"3","author":"MB Poh-Fitzpatrick","year":"1986","unstructured":"Poh-Fitzpatrick MB. Molecular and cellular mechanisms of porphyrin photosensitization. Photodermatology. 1986;3(3):148\u201357.","journal-title":"Photodermatology"},{"issue":"1","key":"1046_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1086\/498620","volume":"78","author":"L Gouya","year":"2006","unstructured":"Gouya L, Martin-Schmitt C, Robreau AM, et al. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am J Hum Genet. 2006;78(1):2\u201314. https:\/\/doi.org\/10.1086\/498620.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1046_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1365-2133.2008.08580.x","volume":"159","author":"M Parker","year":"2008","unstructured":"Parker M, Corrigall AV, Hift RJ, Meissner PN. Molecular characterization of erythropoietic protoporphyria in South Africa. Br J Dermatol. 2008;159(1):182\u201391. https:\/\/doi.org\/10.1111\/j.1365-2133.2008.08580.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1046_CR17","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/blood.V93.6.2105.406k28_2105_2110","volume":"93","author":"L Gouya","year":"1999","unstructured":"Gouya L, Puy H, Lamoril J, et al. Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation. Blood. 1999;93(6):2105\u201310.","journal-title":"Blood"},{"issue":"8","key":"1046_CR18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamadermatol.2017.1557","volume":"153","author":"M Balwani","year":"2017","unstructured":"Balwani M, Naik H, Anderson KE, et al. Clinical, biochemical, and genetic characterization of North American patients with erythropoietic protoporphyria and X-linked protoporphyria. JAMA Dermatol. 2017;153(8):789\u201396. https:\/\/doi.org\/10.1001\/jamadermatol.2017.1557.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1046_CR19","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.jaad.2022.08.036","volume":"89","author":"AK Dickey","year":"2023","unstructured":"Dickey AK, Naik H, Keel SB, et al. Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyria. J Am Acad Dermatol. 2023;89(6):1227\u201337. https:\/\/doi.org\/10.1016\/j.jaad.2022.08.036.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1046_CR20","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jaad.2025.12.024","volume":"94","author":"AK Yeung","year":"2026","unstructured":"Yeung AK, Bonkovsky HL, Balwani M, et al. Bitopertin shows efficacy in patients with erythropoietic protoporphyria: results from the randomized, double-blind, placebo-controlled AURORA trial. J Am Acad Dermatol. 2026;94(4):1167\u201376. https:\/\/doi.org\/10.1016\/j.jaad.2025.12.024.","journal-title":"J Am Acad Dermatol"},{"key":"1046_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114132","volume":"158","author":"IM Heerfordt","year":"2023","unstructured":"Heerfordt IM, Lerche CM, Philipsen PA, Wulf HC. Experimental and approved treatments for skin photosensitivity in individuals with erythropoietic protoporphyria or X-linked protoporphyria: a systematic review. Biomed Pharmacother. 2023;158:114132. https:\/\/doi.org\/10.1016\/j.biopha.2022.114132.","journal-title":"Biomed Pharmacother"},{"key":"1046_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2022.102793","volume":"38","author":"IM Heerfordt","year":"2022","unstructured":"Heerfordt IM, Lerche CM, Wulf HC. Cimetidine for erythropoietic protoporphyria. Photodiagnosis Photodyn Ther. 2022;38:102793. https:\/\/doi.org\/10.1016\/j.pdpdt.2022.102793.","journal-title":"Photodiagnosis Photodyn Ther"},{"issue":"5","key":"1046_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamadermatol.2020.0352","volume":"156","author":"D Wensink","year":"2020","unstructured":"Wensink D, Wagenmakers MAEM, Barman-Aks\u00f6zen J, et al. Association of afamelanotide with improved outcomes in patients with erythropoietic protoporphyria in clinical practice. JAMA Dermatol. 2020;156(5):1\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0352.","journal-title":"JAMA Dermatol"},{"issue":"15","key":"1046_CR24","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1056\/NEJMoa2208754","volume":"388","author":"M Balwani","year":"2023","unstructured":"Balwani M, Bonkovsky HL, Levy C, et al. Dersimelagon in erythropoietic protoporphyrias. N Engl J Med. 2023;388(15):1376\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2208754.","journal-title":"N Engl J Med"},{"issue":"18","key":"1046_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI181875","volume":"135","author":"S Ducamp","year":"2025","unstructured":"Ducamp S, Wu M, Putra J, et al. The GLYT1 inhibitor bitopertin mitigates erythroid PPIX production and liver disease in erythroid protoporphyria. J Clin Invest. 2025;135(18):e181875. https:\/\/doi.org\/10.1172\/JCI181875.","journal-title":"J Clin Invest"},{"issue":"6","key":"1046_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/petr.14040","volume":"25","author":"S Malkiel","year":"2021","unstructured":"Malkiel S, Sayed BA, Ng V, et al. Sequential paternal haploidentical donor liver and HSCT in EPP allow discontinuation of immunosuppression post-organ transplant. Pediatr Transplant. 2021;25(6):e14040. https:\/\/doi.org\/10.1111\/petr.14040.","journal-title":"Pediatr Transplant"},{"issue":"4","key":"1046_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.dld.2021.08.007","volume":"54","author":"D Wensink","year":"2022","unstructured":"Wensink D, Coenen S, Wilson JHP, Wagenmakers MAEM, Langendonk JG. Liver involvement in patients with erythropoietic protoporphyria. Dig Liver Dis. 2022;54(4):515\u201320. https:\/\/doi.org\/10.1016\/j.dld.2021.08.007.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"1046_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2119\/molmed.2012.00340","volume":"19","author":"M Balwani","year":"2013","unstructured":"Balwani M, Doheny D, Bishop DF, et al. Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and X-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria. Mol Med. 2013;19(1):26\u201335. https:\/\/doi.org\/10.2119\/molmed.2012.00340.","journal-title":"Mol Med"},{"issue":"9","key":"1046_CR29","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1111\/liv.15965","volume":"44","author":"A Belot","year":"2024","unstructured":"Belot A, Puy H, Hamza I, Bonkovsky HL. Update on heme biosynthesis, tissue-specific regulation, heme transport, relation to iron metabolism and cellular energy. Liver Int. 2024;44(9):2235\u201350. https:\/\/doi.org\/10.1111\/liv.15965.","journal-title":"Liver Int"},{"issue":"3","key":"1046_CR30","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajhg.2008.08.003","volume":"83","author":"SD Whatley","year":"2008","unstructured":"Whatley SD, Ducamp S, Gouya L, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet. 2008;83(3):408\u201314. https:\/\/doi.org\/10.1016\/j.ajhg.2008.08.003.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1046_CR31","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/cge.12562","volume":"89","author":"V Brancaleoni","year":"2016","unstructured":"Brancaleoni V, Balwani M, Granata F, et al. X-chromosomal inactivation directly influences the phenotypic manifestation of X-linked protoporphyria. Clin Genet. 2016;89(1):20\u20136. https:\/\/doi.org\/10.1111\/cge.12562.","journal-title":"Clin Genet"},{"key":"1046_CR32","unstructured":"Balwani M, Desnick R; Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. X-linked protoporphyria. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae. Seattle (WA): University of Washington; 1993. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK121284\/. Accessed 20 Dec 2025."},{"issue":"24","key":"1046_CR33","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1182\/blood.2022018688","volume":"141","author":"RK Leaf","year":"2023","unstructured":"Leaf RK, Dickey AK. How I treat erythropoietic protoporphyria and X-linked protoporphyria. Blood. 2023;141(24):2921\u201331. https:\/\/doi.org\/10.1182\/blood.2022018688.","journal-title":"Blood"},{"issue":"16","key":"1046_CR34","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM198604173141607","volume":"314","author":"S Piomelli","year":"1986","unstructured":"Piomelli S, Poh-Fitzpatrick MB, Seaman C, Skolnick LM, Berdon WE. Complete suppression of the symptoms of congenital erythropoietic porphyria by long-term treatment with high-level transfusions. N Engl J Med. 1986;314(16):1029\u201331. https:\/\/doi.org\/10.1056\/NEJM198604173141607.","journal-title":"N Engl J Med"},{"key":"1046_CR35","unstructured":"Erwin A, Balwani M, Desnick RJ; Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. Congenital erythropoietic porphyria. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae. Seattle (WA): University of Washington. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK154652\/. Accessed 20 Dec 2025."},{"issue":"1","key":"1046_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1055\/s-2007-1007143","volume":"18","author":"RJ Desnick","year":"1998","unstructured":"Desnick RJ, Glass IA, Xu W, Solis C, Astrin KH. Molecular genetics of congenital erythropoietic porphyria. Semin Liver Dis. 1998;18(1):77\u201384. https:\/\/doi.org\/10.1055\/s-2007-1007143.","journal-title":"Semin Liver Dis"},{"issue":"4","key":"1046_CR37","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/j.1365-2133.2012.11154.x","volume":"167","author":"RP Katugampola","year":"2012","unstructured":"Katugampola RP, Anstey AV, Finlay AY, et al. A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases. Br J Dermatol. 2012;167(4):888\u2013900. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11154.x.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1046_CR38","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1182\/blood-2006-06-022848","volume":"109","author":"JD Phillips","year":"2007","unstructured":"Phillips JD, Steensma DP, Pulsipher MA, Spangrude GJ, Kushner JP. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood. 2007;109(6):2618\u201321. https:\/\/doi.org\/10.1182\/blood-2006-06-022848.","journal-title":"Blood"},{"issue":"3","key":"1046_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1515\/cclm.1993.31.3.121","volume":"31","author":"L Verstraeten","year":"1993","unstructured":"Verstraeten L, Van Regemorter N, Pardou A, et al. Biochemical diagnosis of a fatal case of G\u00fcnther\u2019s disease in a newborn with hydrops foetalis. Eur J Clin Chem Clin Biochem. 1993;31(3):121\u20138. https:\/\/doi.org\/10.1515\/cclm.1993.31.3.121.","journal-title":"Eur J Clin Chem Clin Biochem"},{"issue":"21","key":"1046_CR40","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1182\/blood.2020006037","volume":"136","author":"JM Blouin","year":"2020","unstructured":"Blouin JM, Ged C, Lalanne M, et al. Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria. Blood. 2020;136(21):2457\u201368. https:\/\/doi.org\/10.1182\/blood.2020006037.","journal-title":"Blood"},{"issue":"3","key":"1046_CR41","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3324\/haematol.2019.228270","volume":"106","author":"A Mirmiran","year":"2021","unstructured":"Mirmiran A, Poli A, Ged C, et al. Phlebotomy as an efficient long-term treatment of congenital erythropoietic porphyria. Haematologica. 2021;106(3):913\u20137. https:\/\/doi.org\/10.3324\/haematol.2019.228270.","journal-title":"Haematologica"},{"issue":"2","key":"1046_CR42","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1067\/mjd.2001.114730","volume":"45","author":"FA Harada","year":"2001","unstructured":"Harada FA, Shwayder TA, Desnick RJ, Lim HW. Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. J Am Acad Dermatol. 2001;45(2):279\u201382. https:\/\/doi.org\/10.1067\/mjd.2001.114730.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1046_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060485","volume":"11","author":"G Bernardo-Seisdedos","year":"2021","unstructured":"Bernardo-Seisdedos G, Charco JM, SanJuan I, et al. Improving the pharmacological properties of ciclopirox for its use in congenital erythropoietic porphyria. J Pers Med. 2021;11(6):485. https:\/\/doi.org\/10.3390\/jpm11060485.","journal-title":"J Pers Med"},{"issue":"459","key":"1046_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat7467","volume":"10","author":"P Urquiza","year":"2018","unstructured":"Urquiza P, La\u00edn A, Sanz-Parra A, et al. Repurposing ciclopirox as a pharmacological chaperone in a model of congenital erythropoietic porphyria. Sci Transl Med. 2018;10(459):eaat7467. https:\/\/doi.org\/10.1126\/scitranslmed.aat7467.","journal-title":"Sci Transl Med"},{"issue":"8","key":"1046_CR45","doi-asserted-by":"publisher","first-page":"831","DOI":"10.4045\/tidsskr.13.0649","volume":"134","author":"M Mykletun","year":"2014","unstructured":"Mykletun M, Aarsand AK, St\u00f8le E, et al. Porphyrias in Norway. Tidsskr Laegeforen. 2014;134(8):831\u20136. https:\/\/doi.org\/10.4045\/tidsskr.13.0649.","journal-title":"Tidsskr Laegeforen."},{"key":"1046_CR46","unstructured":"Shah A, Killeen RB, Bhatt H. Porphyria cutanea tarda. In: StatPearls. StatPearls Publishing; 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563209\/. Accessed 20 Dec 2025."},{"issue":"5","key":"1046_CR47","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.bpg.2010.07.002","volume":"24","author":"J Frank","year":"2010","unstructured":"Frank J, Poblete-Guti\u00e9rrez P. Porphyria cutanea tarda: when skin meets liver. Best Pract Res Clin Gastroenterol. 2010;24(5):735\u201345. https:\/\/doi.org\/10.1016\/j.bpg.2010.07.002.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"1046_CR48","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1182\/hematology.2024000664","volume":"2024","author":"RK Leaf","year":"2024","unstructured":"Leaf RK, Dickey AK. Porphyria cutanea tarda: a unique iron-related disorder. Hematol Am Soc Hematol Educ Program. 2024;2024(1):450\u20136. https:\/\/doi.org\/10.1182\/hematology.2024000664.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"1046_CR49","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.V95.5.1565.005k42_1565_1571","volume":"95","author":"ZJ Bulaj","year":"2000","unstructured":"Bulaj ZJ, Phillips JD, Ajioka RS, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood. 2000;95(5):1565\u201371. https:\/\/doi.org\/10.1182\/blood.V95.5.1565.005k42_1565_1571.","journal-title":"Blood"},{"issue":"3","key":"1046_CR50","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ymgme.2019.01.004","volume":"128","author":"AK Singal","year":"2019","unstructured":"Singal AK. Porphyria cutanea tarda: recent update. Mol Genet Metab. 2019;128(3):271\u201381. https:\/\/doi.org\/10.1016\/j.ymgme.2019.01.004.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"1046_CR51","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cgh.2009.11.017","volume":"8","author":"S Jalil","year":"2010","unstructured":"Jalil S, Grady JJ, Lee C, Anderson KE. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2010;8(3):297-302.e1. https:\/\/doi.org\/10.1016\/j.cgh.2009.11.017.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"1046_CR52","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1365-2230.2001.00825.x","volume":"26","author":"RPE Sarkany","year":"2001","unstructured":"Sarkany RPE. The management of porphyria cutanea tarda. Clin Exp Dermatol. 2001;26(3):225\u201332. https:\/\/doi.org\/10.1046\/j.1365-2230.2001.00825.x.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"1046_CR53","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/ijd.12305","volume":"52","author":"ME Horner","year":"2013","unstructured":"Horner ME, Alikhan A, Tintle S, Tortorelli S, Davis DMR, Hand JL. Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopathology. Int J Dermatol. 2013;52(12):1464\u201380. https:\/\/doi.org\/10.1111\/ijd.12305.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1046_CR54","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1600-0560.1992.tb01557.x","volume":"19","author":"B Maynard","year":"1992","unstructured":"Maynard B, Peters MS. Histologic and immunofluorescence study of cutaneous porphyrias. J Cutan Pathol. 1992;19(1):40\u20137. https:\/\/doi.org\/10.1111\/j.1600-0560.1992.tb01557.x.","journal-title":"J Cutan Pathol"},{"issue":"1","key":"1046_CR55","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/00000441-198301000-00001","volume":"285","author":"C Di Padova","year":"1983","unstructured":"Di Padova C, Marchesi L, Cainelli T, et al. Effects of phlebotomy on urinary porphyrin pattern and liver histology in patients with porphyria cutanea tarda. Am J Med Sci. 1983;285(1):2\u201312. https:\/\/doi.org\/10.1097\/00000441-198301000-00001.","journal-title":"Am J Med Sci"},{"issue":"4","key":"1046_CR56","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1046\/j.1440-0960.2000.00437.x","volume":"41","author":"NR Bleasel","year":"2000","unstructured":"Bleasel NR, Varigos GA. Porphyria cutanea tarda. Australas J Dermatol. 2000;41(4):197\u2013206. https:\/\/doi.org\/10.1046\/j.1440-0960.2000.00437.x (quiz 207\u20138).","journal-title":"Australas J Dermatol"},{"issue":"12","key":"1046_CR57","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.cgh.2012.08.038","volume":"10","author":"AK Singal","year":"2012","unstructured":"Singal AK, Kormos-Hallberg C, Lee C, et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2012;10(12):1402\u20139. https:\/\/doi.org\/10.1016\/j.cgh.2012.08.038.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"1046_CR58","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1007\/s10620-023-07859-8","volume":"68","author":"HL Bonkovsky","year":"2023","unstructured":"Bonkovsky HL, Rudnick SP, Ma CD, et al. Ledipasvir\/sofosbuvir is effective as sole treatment of porphyria cutanea tarda with chronic hepatitis C. Dig Dis Sci. 2023;68(6):2738\u201346. https:\/\/doi.org\/10.1007\/s10620-023-07859-8.","journal-title":"Dig Dis Sci"},{"key":"1046_CR59","doi-asserted-by":"publisher","first-page":"17.20.1","DOI":"10.1002\/0471142905.hg1720s86","volume":"86","author":"VMS Ramanujam","year":"2015","unstructured":"Ramanujam VMS, Anderson KE. Porphyria diagnostics: Part 1: A brief overview of the porphyrias. Curr Protoc Hum Genet. 2015;86:17.20.1-17.20.26. https:\/\/doi.org\/10.1002\/0471142905.hg1720s86.","journal-title":"Curr Protoc Hum Genet"},{"issue":"6","key":"1046_CR60","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/S0190-9622(84)70267-2","volume":"11","author":"HW Lim","year":"1984","unstructured":"Lim HW, Poh-Fitzpatrick MB. Hepatoerythropoietic porphyria: a variant of childhood-onset porphyria cutanea tarda: porphyrin profiles and enzymatic studies of two cases in a family. J Am Acad Dermatol. 1984;11(6):1103\u201311. https:\/\/doi.org\/10.1016\/S0190-9622(84)70267-2.","journal-title":"J Am Acad Dermatol"},{"issue":"8226","key":"1046_CR61","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S0140-6736(81)91615-9","volume":"317","author":"GH Elder","year":"1981","unstructured":"Elder GH, Smith SG, Herrero C, et al. Hepatoerythropoietic porphyria: a new uroporphyrinogen decarboxylase defect of homozygous porphyria cutanea tarda? Lancet. 1981;317(8226):916\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(81)91615-9.","journal-title":"Lancet"},{"key":"1046_CR62","unstructured":"Rudnick S, Phillips J, Bonkovsky H; Porphyrias Consortium of the Rare Diseases Clinical Research Network. Hepatoerythropoietic porphyria. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae. Seattle (WA): University of Washington; 1993. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK169003\/. Accessed 20 Dec 2025."},{"issue":"3","key":"1046_CR63","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ymgme.2018.11.013","volume":"128","author":"Y Weiss","year":"2019","unstructured":"Weiss Y, Chen B, Yasuda M, Nazarenko I, Anderson KE, Desnick RJ. Porphyria cutanea tarda and hepatoerythropoietic porphyria: identification of 19 novel uroporphyrinogen III decarboxylase mutations. Mol Genet Metab. 2019;128(3):363\u20136. https:\/\/doi.org\/10.1016\/j.ymgme.2018.11.013.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"1046_CR64","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/1523-1747.ep12605953","volume":"104","author":"AG Roberts","year":"1995","unstructured":"Roberts AG, Elder GH, De Salamanca RE, Herrero C, Lecha M, Mascaro JM. A mutation (G281E) of the human uroporphyrinogen decarboxylase gene causes both hepatoerythropoietic porphyria and overt familial porphyria cutanea tarda: biochemical and genetic studies on Spanish patients. J Invest Dermatol. 1995;104(4):500\u20132. https:\/\/doi.org\/10.1111\/1523-1747.ep12605953.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"1046_CR65","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1023\/a:1005313024076","volume":"20","author":"GH Elder","year":"1997","unstructured":"Elder GH. Hepatic porphyrias in children. J Inherit Metab Dis. 1997;20(2):237\u201346. https:\/\/doi.org\/10.1023\/a:1005313024076.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"1046_CR66","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archdermatol.2010.89","volume":"146","author":"JL Cantatore-Francis","year":"2010","unstructured":"Cantatore-Francis JL, Cohen J, Balwani M, et al. Hepatoerythropoietic porphyria misdiagnosed as child abuse: cutaneous, arthritic, and hematologic manifestations in siblings with a novel UROD mutation. Arch Dermatol. 2010;146(5):529\u201333. https:\/\/doi.org\/10.1001\/archdermatol.2010.89.","journal-title":"Arch Dermatol"},{"issue":"3","key":"1046_CR67","doi-asserted-by":"publisher","DOI":"10.12890\/2025_005198","volume":"12","author":"\u00c7 Kaya","year":"2025","unstructured":"Kaya \u00c7, Heydari A, K\u0131z\u0131lay O, K\u0131z\u0131lay O, Sezgin G. Hepatoerythropoietic porphyria with coexisting BTD and CNGB1 genetic mutations: a first case report. Eur J Case Rep Intern Med. 2025;12(3):005198. https:\/\/doi.org\/10.12890\/2025_005198.","journal-title":"Eur J Case Rep Intern Med"},{"issue":"2","key":"1046_CR68","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1182\/blood.V94.2.465","volume":"94","author":"A Fontanellas","year":"1999","unstructured":"Fontanellas A, Mazurier F, Moreau-Gaudry F, Belloc F, Ged C, de Verneuil H. Correction of uroporphyrinogen decarboxylase deficiency (hepatoerythropoietic porphyria) in Epstein-Barr virus-transformed B-cell lines by retrovirus-mediated gene transfer: fluorescence-based selection of transduced cells. Blood. 1999;94(2):465\u201374.","journal-title":"Blood"},{"key":"1046_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01018","volume":"10","author":"Y Fu","year":"2019","unstructured":"Fu Y, Jia J, Yue L, et al. Systematically analyzing the pathogenic variations for acute intermittent porphyria. Front Pharmacol. 2019;10:1018. https:\/\/doi.org\/10.3389\/fphar.2019.01018.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1046_CR70","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1046\/j.1365-2796.2003.01172.x","volume":"254","author":"C Andersson","year":"2003","unstructured":"Andersson C, Innala E, B\u00e4ckstr\u00f6m T. Acute intermittent porphyria in women: Clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden. J Intern Med. 2003;254(2):176\u201383. https:\/\/doi.org\/10.1046\/j.1365-2796.2003.01172.x.","journal-title":"J Intern Med"},{"issue":"3","key":"1046_CR71","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ymgme.2018.12.006","volume":"128","author":"E Storjord","year":"2019","unstructured":"Storjord E, Dahl JA, Landsem A, et al. Lifestyle factors including diet and biochemical biomarkers in acute intermittent porphyria: results from a case-control study in northern Norway. Mol Genet Metab. 2019;128(3):254\u201370. https:\/\/doi.org\/10.1016\/j.ymgme.2018.12.006.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"1046_CR72","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.cell.2005.06.040","volume":"122","author":"C Handschin","year":"2005","unstructured":"Handschin C, Lin J, Rhee J, et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell. 2005;122(4):505\u201315. https:\/\/doi.org\/10.1016\/j.cell.2005.06.040.","journal-title":"Cell"},{"key":"1046_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2021-207647","author":"D Schulenburg-Brand","year":"2022","unstructured":"Schulenburg-Brand D, Stewart F, Stein P, Rees D, Badminton M. Update on the diagnosis and management of the autosomal dominant acute hepatic porphyrias. J Clin Pathol. 2022. https:\/\/doi.org\/10.1136\/jclinpath-2021-207647 (Epub ahead of print).","journal-title":"J Clin Pathol"},{"issue":"3","key":"1046_CR74","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1046\/j.1365-2796.1997.00189.x","volume":"242","author":"Y Nordmann","year":"1997","unstructured":"Nordmann Y, Puy H, Da Silva V, et al. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J Intern Med. 1997;242(3):213\u20137. https:\/\/doi.org\/10.1046\/j.1365-2796.1997.00189.x.","journal-title":"J Intern Med"},{"issue":"11","key":"1046_CR75","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/humu.23067","volume":"37","author":"B Chen","year":"2016","unstructured":"Chen B, Solis-Villa C, Hakenberg J, et al. Acute intermittent porphyria: predicted pathogenicity of HMBS variants indicates extremely low penetrance of the autosomal dominant disease. Hum Mutat. 2016;37(11):1215\u201322. https:\/\/doi.org\/10.1002\/humu.23067.","journal-title":"Hum Mutat"},{"issue":"4","key":"1046_CR76","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1034\/j.1399-0004.2002.620406.x","volume":"62","author":"Y Floderus","year":"2002","unstructured":"Floderus Y, Shoolingin-Jordan PM, Harper P. Acute intermittent porphyria in Sweden: molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin Genet. 2002;62(4):288\u201397. https:\/\/doi.org\/10.1034\/j.1399-0004.2002.620406.x.","journal-title":"Clin Genet"},{"issue":"12","key":"1046_CR77","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.amjmed.2014.06.036","volume":"127","author":"HL Bonkovsky","year":"2014","unstructured":"Bonkovsky HL, Maddukuri VC, Yazici C, et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med. 2014;127(12):1233\u201341. https:\/\/doi.org\/10.1016\/j.amjmed.2014.06.036.","journal-title":"Am J Med"},{"issue":"3","key":"1046_CR78","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jemermed.2015.04.034","volume":"49","author":"S Besur","year":"2015","unstructured":"Besur S, Schmeltzer P, Bonkovsky HL. Acute porphyrias. J Emerg Med. 2015;49(3):305\u201312. https:\/\/doi.org\/10.1016\/j.jemermed.2015.04.034.","journal-title":"J Emerg Med"},{"issue":"2","key":"1046_CR79","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/ki.2015.97","volume":"88","author":"N Pallet","year":"2015","unstructured":"Pallet N, Mami I, Schmitt C, et al. High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. Kidney Int. 2015;88(2):386\u201395. https:\/\/doi.org\/10.1038\/ki.2015.97.","journal-title":"Kidney Int"},{"issue":"2","key":"1046_CR80","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.amjms.2021.03.004","volume":"362","author":"KE Anderson","year":"2021","unstructured":"Anderson KE, Lobo R, Salazar D, et al. Biochemical diagnosis of acute hepatic porphyria: updated expert recommendations for primary care physicians. Am J Med Sci. 2021;362(2):113\u201321. https:\/\/doi.org\/10.1016\/j.amjms.2021.03.004.","journal-title":"Am J Med Sci"},{"issue":"4","key":"1046_CR81","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/hep.29313","volume":"66","author":"M Balwani","year":"2017","unstructured":"Balwani M, Wang B, Anderson KE, et al. Acute hepatic porphyrias: recommendations for evaluation and long-term management. Hepatology. 2017;66(4):1314\u201322. https:\/\/doi.org\/10.1002\/hep.29313.","journal-title":"Hepatology"},{"issue":"8650","key":"1046_CR82","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S0140-6736(89)92688-3","volume":"333","author":"AL Herrick","year":"1989","unstructured":"Herrick AL, Moore MR, Mccoll KEL, Cook A, Goldberg A. Controlled trial of haem arginate in acute hepatic porphyria. Lancet. 1989;333(8650):1295\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(89)92688-3.","journal-title":"Lancet"},{"issue":"8","key":"1046_CR83","first-page":"1050","volume":"86","author":"HL Bonkovsky","year":"1991","unstructured":"Bonkovsky HL, Healey JF, Lourie AN, Gerron GG. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol. 1991;86(8):1050\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1046_CR84","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/ijc.26075","volume":"130","author":"JM Lee","year":"2012","unstructured":"Lee JM, Lee WH, Kay HY, Eun-sook K, Moon A, Kim SG. Hemin, an iron-binding porphyrin, inhibits HIF-1\u03b1 induction through its binding with heat shock protein 90. Int J Cancer. 2012;130(3):716\u201327. https:\/\/doi.org\/10.1002\/ijc.26075.","journal-title":"Int J Cancer"},{"issue":"6","key":"1046_CR85","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/13696998.2020.1724118","volume":"23","author":"B Blaylock","year":"2020","unstructured":"Blaylock B, Epstein J, Stickler P. Real-world annualized healthcare utilization and expenditures among insured US patients with acute intermittent porphyria (AIP) treated with hemin. J Med Econ. 2020;23(6):537\u201345. https:\/\/doi.org\/10.1080\/13696998.2020.1724118.","journal-title":"J Med Econ"},{"key":"1046_CR86","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/8904_2015_411","volume":"22","author":"JT Marsden","year":"2015","unstructured":"Marsden JT, Guppy S, Stein P, et al. Audit of the use of regular haem arginate infusions in patients with acute porphyria to prevent recurrent symptoms. JIMD Rep. 2015;22:57\u201365. https:\/\/doi.org\/10.1007\/8904_2015_411.","journal-title":"JIMD Rep."},{"issue":"24","key":"1046_CR87","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","volume":"382","author":"M Balwani","year":"2020","unstructured":"Balwani M, Sardh E, Ventura P, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020;382(24):2289\u2013301. https:\/\/doi.org\/10.1056\/NEJMoa1913147.","journal-title":"N Engl J Med"},{"key":"1046_CR88","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/8904_2017_2","volume":"36","author":"D Schulenburg-Brand","year":"2017","unstructured":"Schulenburg-Brand D, Gardiner T, Guppy S, et al. An audit of the use of gonadorelin analogues to prevent recurrent acute symptoms in patients with acute porphyria in the United Kingdom. JIMD Rep. 2017;36:99\u2013107. https:\/\/doi.org\/10.1007\/8904_2017_2.","journal-title":"JIMD Rep."},{"key":"1046_CR89","unstructured":"Singal AK, Anderson KE. Variegate porphyria. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae. Seattle (WA): University of Washington; 1993. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK121283\/. Accessed 8 Dec 2025."},{"issue":"2","key":"1046_CR90","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1096\/fj.10-170811","volume":"25","author":"X Qin","year":"2011","unstructured":"Qin X, Tan Y, Wang L, et al. Structural insight into human variegate porphyria disease. FASEB J. 2011;25(2):653\u201364. https:\/\/doi.org\/10.1096\/fj.10-170811.","journal-title":"FASEB J"},{"issue":"5","key":"1046_CR91","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10545-012-9544-4","volume":"36","author":"G Elder","year":"2013","unstructured":"Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2013;36(5):849\u201357. https:\/\/doi.org\/10.1007\/s10545-012-9544-4.","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"1046_CR92","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1136\/jclinpath-2011-200276","volume":"65","author":"RJ Hift","year":"2012","unstructured":"Hift RJ, Peters TJ, Meissner PN. A review of the clinical presentation, natural history and inheritance of variegate porphyria: its implausibility as the source of the \u2018Royal Malady.\u2019 J Clin Pathol. 2012;65(3):200\u20135. https:\/\/doi.org\/10.1136\/jclinpath-2011-200276.","journal-title":"J Clin Pathol"},{"issue":"7","key":"1046_CR93","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/lt.20136","volume":"10","author":"N Stojeba","year":"2004","unstructured":"Stojeba N, Meyer C, Jeanpierre C, et al. Recovery from a variegate porphyria by a liver transplantation. Liver Transplant. 2004;10(7):935\u20138. https:\/\/doi.org\/10.1002\/lt.20136.","journal-title":"Liver Transplant"},{"issue":"9","key":"1046_CR94","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1111\/liv.15979","volume":"44","author":"D Jeric\u00f3","year":"2024","unstructured":"Jeric\u00f3 D, C\u00f3rdoba KM, Urigo F, et al. Exploring current and emerging therapies for porphyrias. Liver Int. 2024;44(9):2174\u201390. https:\/\/doi.org\/10.1111\/liv.15979.","journal-title":"Liver Int"},{"key":"1046_CR95","unstructured":"European Medicines Agency. EU\/3\/24\/2947: orphan designation for treatment of variegate porphyria. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-24-2947. Accessed 16 Apr 2026."},{"key":"1046_CR96","unstructured":"Wang B, Bissell DM. Hereditary coproporphyria. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews\u00ae. Seattle (WA): University of Washington; 1993. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK114807\/. Accessed 8 Dec 2025."},{"key":"1046_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2023.100964","volume":"35","author":"X Kang","year":"2023","unstructured":"Kang X, Shimada S, Miyahara H, Higuchi K, Mori M. BALB.NCT-Cpoxnct is a unique mouse model of hereditary coproporphyria. Mol Genet Metab Rep. 2023;35:100964. https:\/\/doi.org\/10.1016\/j.ymgmr.2023.100964.","journal-title":"Mol Genet Metab Rep"},{"issue":"6","key":"1046_CR98","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/s0009-9120(00)00159-4","volume":"33","author":"A K\u00fchnel","year":"2000","unstructured":"K\u00fchnel A, Gross U, Doss MO. Hereditary coproporphyria in Germany: clinical-biochemical studies in 53 patients. Clin Biochem. 2000;33(6):465\u201373. https:\/\/doi.org\/10.1016\/s0009-9120(00)00159-4.","journal-title":"Clin Biochem"},{"issue":"1","key":"1046_CR99","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/jdv.15769","volume":"34","author":"Y Edel","year":"2020","unstructured":"Edel Y, Mamet R, Snast I, et al. Epidemiology of cutaneous porphyria in Israel: a nationwide cohort study. J Eur Acad Dermatol Venereol. 2020;34(1):184\u20137. https:\/\/doi.org\/10.1111\/jdv.15769.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1046_CR100","unstructured":"Mohan G, Madan A. ALA dehydratase deficiency porphyria. In: StatPearls. StatPearls Publishing; 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560836\/. Accessed 8 Dec 2025."},{"issue":"4","key":"1046_CR101","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ymgme.2020.10.011","volume":"131","author":"AP Lahiji","year":"2020","unstructured":"Lahiji AP, Anderson KE, Chan A, Simon A, Desnick RJ, Ramanujam VMS. 5-Aminolevulinate dehydratase porphyria: update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin. Mol Genet Metab. 2020;131(4):418\u201323. https:\/\/doi.org\/10.1016\/j.ymgme.2020.10.011.","journal-title":"Mol Genet Metab"},{"issue":"9","key":"1046_CR102","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.92741","volume":"17","author":"I Fatima","year":"2025","unstructured":"Fatima I, Awais KAD, Sehbai A, Tareen AAK, Shaharyar M. Neurovisceral syndrome in a patient with monoclonal gammopathy of undetermined significance: a confirmed case of variegate porphyria. Cureus. 2025;17(9):e92741. https:\/\/doi.org\/10.7759\/cureus.92741.","journal-title":"Cureus."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01046-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01046-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01046-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:21:54Z","timestamp":1784186514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01046-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1046"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01046-x","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No funding was received for the preparation of this article.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stanislav N. Tolkachjov is an investigator\/speaker for Bioventus,\u00a0Kerecis, Boehringer Ingelheim, Regeneron, Leo Pharma, and\u00a0CASTLE. Tasneem F. Mohammad is an investigator for Mitusishi Tanabe, Clinuvel, and Disc Medicine and has served on an advisory board for Disc Medicine. Ivo Abraham is the Quantitative Methods Editor of\u00a0\n                      JAMA Dermatology\n                      ,\u00a0which is a compensated editorship contracted to Matrix45. He is the Editor-in-Chief of the\u00a0\n                      Journal of Medical Economics\n                      , which is an uncompensated editorship but\u00a0for which he receives an annual allotment of submissions free of publication charges. Daniel Grove is a consultant for Disc Medicine and has served on their advisory committees. Toan N. Vu, Sahithi Talasila, George M. Jeha, Umer Nadir, and Henry W. Lim have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board approval was not required because this study is a review of previously published literature and does not involve human participants or identifiable patient data.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data availability is not applicable, as no new data were created or analyzed in this study.","order":6,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: TNV, ST, UN; methodology: TNV, ST; formal analysis and investigation: TNV; writing (original draft preparation): TNV; writing (review and editing): TNV, ST, GMJ, UN, TFM, HWL, IA, DG, SNT; supervision: SNT. All authors have read and approved the final version.","order":8,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}